Literature DB >> 7877542

Systemic bacterial and fungal infections in infants in Australian neonatal units. Australian Study Group for Neonatal Infections.

D Isaacs1, C P Barfield, K Grimwood, A J McPhee, C Minutillo, D I Tudehope.   

Abstract

OBJECTIVE: To examine the pattern and incidence of sepsis occurring in neonatal units in Australia.
DESIGN: A one-year prospective study of babies with systemic sepsis within 48 hours of birth (early-onset sepsis) or after this time (late-onset sepsis) in seven Australian neonatal units. Systemic sepsis was defined as clinical sepsis, plus either positive bacterial or fungal culture of blood and/or cerebrospinal fluid, or group B streptococcal antigen detected in the urine.
RESULTS: There were 241 episodes of sepsis, affecting 234 babies. One quarter (61) were early-onset, a rate of 2.2 per 1000 live births. Group B streptococcus (GBS) was the commonest cause of early-onset sepsis, with a rate of 1.3 per 1000 live births. The incidence of early-onset GBS sepsis was lower at a hospital which screened for maternal carriage and used intrapartum antibiotic prophylaxis for all carriers. The rate of late-onset sepsis was 4.4 per 1000 live births and coagulase-negative staphylococci were the commonest cause. Meningitis occurred in 23% of babies with early-onset and in 10% with late-onset sepsis. The mortality from early-onset sepsis was 15%, and from late-onset sepsis was 9%. There were no major regional variations, other than for GBS.
CONCLUSIONS: The incidence of and mortality from neonatal sepsis is comparable to other countries, and shows no major regional variation. The use of intrapartum antibiotics may reduce the incidence of neonatal GBS sepsis. There are no previous comparable data on neonatal infections in Australia.

Entities:  

Mesh:

Year:  1995        PMID: 7877542     DOI: 10.5694/j.1326-5377.1995.tb126024.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  20 in total

1.  Neonatal sepsis: Staphylococcus aureus as the predominant pathogen.

Authors:  G Karthikeyan; K Premkumar
Journal:  Indian J Pediatr       Date:  2001-08       Impact factor: 1.967

2.  Outcomes for high risk New Zealand newborn infants in 1998-1999: a population based, national study.

Authors:  A E Cust; B A Darlow; D A Donoghue
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

3.  Early onset neonatal meningitis in Australia and New Zealand, 1992-2002.

Authors:  M May; A J Daley; S Donath; D Isaacs
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05-05       Impact factor: 5.747

Review 4.  Neonatal brain infections.

Authors:  Jacques F Schneider
Journal:  Pediatr Radiol       Date:  2011-04-27

Review 5.  Diagnostic tests for bacterial infection from birth to 90 days--a systematic review.

Authors:  P W Fowlie; B Schmidt
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-03       Impact factor: 5.747

Review 6.  Early-onset neonatal sepsis.

Authors:  Kari A Simonsen; Ann L Anderson-Berry; Shirley F Delair; H Dele Davies
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

Review 7.  Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia.

Authors:  Mohan Pammi; Peter Brocklehurst
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

8.  Incidence of Late Onset Neonatal Sepsis in Very Low Birth Weight Infants in a Tertiary Hospital: An ongoing challenge.

Authors:  Khalid M Alfaleh
Journal:  Sultan Qaboos Univ Med J       Date:  2010-07-19

9.  Comparison of the pattern of nosocomial infection between the neonatal intensive care units of hospitals kuala terengganu and universiti sains malaysia, kelantan.

Authors:  W Wan Hanifah; J Lee; B Quah
Journal:  Malays J Med Sci       Date:  2000-01

Review 10.  Reappraisal of guidelines for management of neonates with suspected early-onset sepsis.

Authors:  William E Benitz; James L Wynn; Richard A Polin
Journal:  J Pediatr       Date:  2015-01-29       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.